Chen Sun1, Huimin Zhu1, Yun Wang1, Yichen Han1, Dongdong Zhang1, Xi Cao1, Mihribangvl Alip1, Min Nie1, Xue Xu1, Liangjing Lv2, Xuebing Feng3, Lingyun Sun4, Dandan Wang5. 1. Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing, Jiangsu, 210008, People's Republic of China. 2. Department of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China. 3. Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing, Jiangsu, 210008, People's Republic of China. xb.feng@163.com. 4. Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing, Jiangsu, 210008, People's Republic of China. lingyunsun@nju.edu.cn. 5. Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing, Jiangsu, 210008, People's Republic of China. dandanwangffd@nju.edu.cn.
Abstract
BACKGROUND: Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by extensive fibrosis and vascular damage. Vasculopathy, activation of the immune system, and diffuse fibrosis are all involved in the fatal pathogenesis of SSc. However, little metabolomic research has been conducted in SSc. METHODS: This study included 30 SSc patients and 30 healthy individuals. The metabolite differences in serum samples were analyzed using ultra-high-pressure liquid chromatography and quadrupole-time-of-flight mass spectrometry. Meanwhile, serum metabolites were analyzed in patients with systemic involvement (lung or skin fibrosis). RESULTS: A total of 2360 ion peaks were detected, all of which were attributable to 38 metabolites. These metabolites primarily consisted of fatty acids, amino acids, and glycerophospholipids, which were the major metabolic pathways altered in SSc patients. Glutamine metabolism was the main pathway altered in SSc patients with lung involvement, whereas amino acid metabolism and steroid hormone biosynthesis were the main pathways altered in SSc patients with skin involvement. CONCLUSION: These findings suggested that metabolic profiles and pathways differed between SSc patients and healthy people, potentially providing new targets for SSc-directed therapeutics and diagnostics. Key Points • Metabolic profiles and pathways differed between SSc patients and healthy people. • The levels of trans-dehydroandrosterone are substantially lower in lcSSc than in dcSSc, potentially providing new targets for SSc patients with skin involvement. • L-glutamine could be used as a serum metabolic marker and a therapeutic target for SSc patients with lung involvement.
BACKGROUND: Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by extensive fibrosis and vascular damage. Vasculopathy, activation of the immune system, and diffuse fibrosis are all involved in the fatal pathogenesis of SSc. However, little metabolomic research has been conducted in SSc. METHODS: This study included 30 SSc patients and 30 healthy individuals. The metabolite differences in serum samples were analyzed using ultra-high-pressure liquid chromatography and quadrupole-time-of-flight mass spectrometry. Meanwhile, serum metabolites were analyzed in patients with systemic involvement (lung or skin fibrosis). RESULTS: A total of 2360 ion peaks were detected, all of which were attributable to 38 metabolites. These metabolites primarily consisted of fatty acids, amino acids, and glycerophospholipids, which were the major metabolic pathways altered in SSc patients. Glutamine metabolism was the main pathway altered in SSc patients with lung involvement, whereas amino acid metabolism and steroid hormone biosynthesis were the main pathways altered in SSc patients with skin involvement. CONCLUSION: These findings suggested that metabolic profiles and pathways differed between SSc patients and healthy people, potentially providing new targets for SSc-directed therapeutics and diagnostics. Key Points • Metabolic profiles and pathways differed between SSc patients and healthy people. • The levels of trans-dehydroandrosterone are substantially lower in lcSSc than in dcSSc, potentially providing new targets for SSc patients with skin involvement. • L-glutamine could be used as a serum metabolic marker and a therapeutic target for SSc patients with lung involvement.
Authors: Frank van den Hoogen; Dinesh Khanna; Jaap Fransen; Sindhu R Johnson; Murray Baron; Alan Tyndall; Marco Matucci-Cerinic; Raymond P Naden; Thomas A Medsger; Patricia E Carreira; Gabriela Riemekasten; Philip J Clements; Christopher P Denton; Oliver Distler; Yannick Allanore; Daniel E Furst; Armando Gabrielli; Maureen D Mayes; Jacob M van Laar; James R Seibold; Laszlo Czirjak; Virginia D Steen; Murat Inanc; Otylia Kowal-Bielecka; Ulf Müller-Ladner; Gabriele Valentini; Douglas J Veale; Madelon C Vonk; Ulrich A Walker; Lorinda Chung; David H Collier; Mary Ellen Csuka; Barri J Fessler; Serena Guiducci; Ariane Herrick; Vivien M Hsu; Sergio Jimenez; Bashar Kahaleh; Peter A Merkel; Stanislav Sierakowski; Richard M Silver; Robert W Simms; John Varga; Janet E Pope Journal: Arthritis Rheum Date: 2013-10-03
Authors: Álvaro Fernández-Ochoa; Carl Brunius; Isabel Borrás-Linares; Rosa Quirantes-Piné; María de la Luz Cádiz-Gurrea; Marta E Alarcón Riquelme; Antonio Segura-Carretero Journal: J Proteome Res Date: 2020-06-08 Impact factor: 4.466
Authors: Yannick Allanore; Robert Simms; Oliver Distler; Maria Trojanowska; Janet Pope; Christopher P Denton; John Varga Journal: Nat Rev Dis Primers Date: 2015-04-23 Impact factor: 52.329
Authors: Thomas Bögl; Franz Mlynek; Markus Himmelsbach; Norbert Sepp; Wolfgang Buchberger; Marija Geroldinger-Simić Journal: Biomedicines Date: 2022-03-04